Overview

Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil

Status:
Terminated
Trial end date:
2020-12-23
Target enrollment:
Participant gender:
Summary
Acute and chronic hemodynamic dose-response and safety evaluation of LIQ861 in PAH subjects.
Phase:
Phase 2
Details
Lead Sponsor:
Liquidia Technologies, Inc.
Collaborator:
FGK Clinical Research GmbH
Treatments:
Treprostinil